Analysts at BTIG Research began coverage on shares of Akebia Therapeutics (NASDAQ:AKBA) in a note issued to investors on Thursday, Marketbeat.com reports. The firm set a “buy” rating and a $30.00 price target on the biopharmaceutical company’s stock. BTIG Research’s target price indicates a potential upside of 93.55% from the stock’s previous close.

Other analysts have also issued reports about the stock. ValuEngine raised shares of Akebia Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, September 1st. BidaskClub raised shares of Akebia Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, August 16th. HC Wainwright reissued a “buy” rating and issued a $24.00 price objective on shares of Akebia Therapeutics in a research report on Wednesday, August 9th. Royal Bank Of Canada began coverage on shares of Akebia Therapeutics in a research report on Thursday, September 14th. They issued a “sector perform” rating and a $17.00 price objective on the stock. Finally, Mizuho reissued a “buy” rating and issued a $24.00 price objective on shares of Akebia Therapeutics in a research report on Thursday, November 9th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and eight have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $21.78.

Shares of Akebia Therapeutics (NASDAQ AKBA) traded up $0.10 during midday trading on Thursday, hitting $15.50. 507,300 shares of the stock traded hands, compared to its average volume of 505,814. Akebia Therapeutics has a 52-week low of $7.78 and a 52-week high of $20.25.

Akebia Therapeutics (NASDAQ:AKBA) last posted its quarterly earnings data on Wednesday, November 8th. The biopharmaceutical company reported ($0.49) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.56) by $0.07. Akebia Therapeutics had a negative net margin of 137.80% and a negative return on equity of 198.85%. The company had revenue of $41.28 million for the quarter, compared to analyst estimates of $34.00 million. sell-side analysts anticipate that Akebia Therapeutics will post -2.25 earnings per share for the current fiscal year.

In other Akebia Therapeutics news, SVP Michel Dahan sold 5,000 shares of the company’s stock in a transaction dated Thursday, September 28th. The shares were sold at an average price of $19.30, for a total value of $96,500.00. Following the transaction, the senior vice president now directly owns 97,224 shares in the company, valued at approximately $1,876,423.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders sold a total of 7,586 shares of company stock worth $147,289 over the last 90 days. Insiders own 7.95% of the company’s stock.

A number of hedge funds have recently modified their holdings of AKBA. Vanguard Group Inc. grew its stake in Akebia Therapeutics by 8.8% in the 1st quarter. Vanguard Group Inc. now owns 1,301,880 shares of the biopharmaceutical company’s stock worth $11,977,000 after acquiring an additional 105,645 shares in the last quarter. Geode Capital Management LLC grew its stake in Akebia Therapeutics by 4.7% in the 1st quarter. Geode Capital Management LLC now owns 330,096 shares of the biopharmaceutical company’s stock worth $3,036,000 after acquiring an additional 14,959 shares in the last quarter. Renaissance Technologies LLC grew its stake in Akebia Therapeutics by 85.2% in the 1st quarter. Renaissance Technologies LLC now owns 386,267 shares of the biopharmaceutical company’s stock worth $3,554,000 after acquiring an additional 177,667 shares in the last quarter. Schwab Charles Investment Management Inc. grew its stake in Akebia Therapeutics by 6.2% in the 1st quarter. Schwab Charles Investment Management Inc. now owns 125,130 shares of the biopharmaceutical company’s stock worth $1,152,000 after acquiring an additional 7,353 shares in the last quarter. Finally, Goldman Sachs Group Inc. grew its stake in Akebia Therapeutics by 1.2% in the 1st quarter. Goldman Sachs Group Inc. now owns 49,277 shares of the biopharmaceutical company’s stock worth $453,000 after acquiring an additional 608 shares in the last quarter. Institutional investors and hedge funds own 62.82% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “BTIG Research Begins Coverage on Akebia Therapeutics (AKBA)” was published by American Banking News and is owned by of American Banking News. If you are reading this news story on another domain, it was copied illegally and republished in violation of US & international copyright and trademark law. The correct version of this news story can be viewed at https://www.americanbankingnews.com/2017/12/07/btig-research-begins-coverage-on-akebia-therapeutics-akba.html.

Akebia Therapeutics Company Profile

Akebia Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of therapeutics based on hypoxia-inducible factor (HIF) biology. The Company’s lead product candidate, vadadustat, is indicated for the treatment of anemia in chronic kidney disease (CKD).

Analyst Recommendations for Akebia Therapeutics (NASDAQ:AKBA)

Receive News & Ratings for Akebia Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akebia Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.